TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile.~* Chronic HCV infection prior to study enrollment.~* Screening laboratory result indicating HCV genotype 1-infection.~* Subject must be treatment naive or previous pegylated interferon/ribavirin treatment experienced.~* Subjects must be on a stable opioid replacement therapy of methadone or buprenorphine ± naloxone for at least 6 months prior to screening.~Exclusion Criteria:~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) at screening.~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir.~* Females who are pregnant or plan to become pregnant, or breastfeeding, or males whose partners are pregnant or planning to become pregnant within 7 months (or per local RBV label) after their last dose of study drug.~* Any current or past clinical evidence of cirrhosis such as ascites or esophageal varices, or prior biopsy showing cirrhosis, e.g., a Metavir Score of \>3 or Ishak score of \> 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Bevacizumab for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Females that are at least 18 years of age.~* Women of childbearing potential must have a negative serum pregnancy test at screening.~* Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting.~* Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic.~* Adequate hepatic, renal and cardiac function~* ECOG score 0-1 and a life expectancy of at least 12 weeks.~* Able to swallow oral medication~* Signed informed consent~Exclusion criteria:~* Pregnancy~* Unstable or symptomatic CNS metastases~* Major surgery within 28 days of enrollment (minor surgery within 7 days).~* Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities.~* A serious non-healing wound, ulcer, or bone fracture at baseline.~* Class II, III or IV heart failure as defined by the NYHA functional classification system~* History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension.~* History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment.~* History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment.~* History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.~* Proteinuria~* Requires concurrent anti-cancer treatment or investigational treatment.~* Known hypersensitivity to either study medication~* Received investigational treatment within 28 days or 5 half-lives, whichever is longer~* Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study~* Requires medication that has been excluded during study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral lapatinib tablets in combination with IV bevacizumab (Type: EXPERIMENTAL): 1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-exposure Option for Reducing HIV in the UK.(PROUD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Born to male gender, age 18 years or more~* Previously attended the enrolling clinic on at least one occasion~* Completed a screen for HIV and STIs~* HIV negative by a routinely used assay within 4 weeks prior to or on the day of randomisation~* Reported unprotected anal intercourse (UAI) on more than one occasion within the 90 days prior to randomisation~* Likely, in the opinion of the volunteer, to have UAI in the next 90 days~* Willing and able to comply with the visit schedule throughout the follow-up period~* Willing and able to provide written informed consent~Exclusion Criteria:~* An acute viral illness that could be due to HIV seroconversion~* Any contraindications to Truvada according to the current package insert~* Treatment for hepatitis B infection indicated or ongoing~* Unlikely, in the opinion of the clinician, to comply with the randomised allocation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm A: Immediate offer of Truvada-PrEP (Type: EXPERIMENTAL): Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
- Arm B: Deferred (12m) offer of Truvada-PrEP (Type: OTHER): Access to Truvada from 12 months after enrolment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy.~* Age between 17 - 35 years.~* Gestational age between 28 and 36 weeks.~* Diagnosis of threatened preterm labor is based on the American College of Obstetricians and Gynaecologists Guidelines (ACOG, 2003): Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation \> 1 and \< 4 cm, and/or Cervical effacement ≥ 80%.~Exclusion Criteria:~* Preterm rupture of membranes.~* Any uterine anomalies or cervical incompetence.~* Chronic illness such as chronic hypertension or kidney disease.~* Diabetes mellitus.~* Abruptio placenta.~* Preeclampsia and HELLP syndrome.~* Fetal anomalies.~* IUGR.~* Smoking.~* Clinical signs of intrauterine infection eg (uterine tenderness, foul vaginal discharge, maternal pyrexia ≥ 38°C and/or maternal leucocytosis).

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- preterm group (Type: None): pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation \> 1 and \< 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
- full term group (Type: None): pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation \> 1 and \< 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female pretreated outpatients between ages 18 and 80 years (inclusive)~* A clinical diagnosis of bilateral blepharospasm (BEB) characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi muscles~* A need for injection of Botulinum toxin (defined by a Jankovic Rating Scale (JRS) severity subscore \>= 2)~* On a stable dose of other medications (if any) used for focal dystonia treatment (e.g. anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the Main Period~* Source documentation of the last two consecutive injection sessions with BOTOX® and a stable satisfactory therapeutic response directly prior to trial entry~* At least 10 weeks must have been passed between the last injection with BOTOX® for BEB and Baseline~Main Exclusion Criteria:~* Atypical variant of BEB caused by inhibition of levator palpebrae muscle~* Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation and/or spinal cord stimulation)~* The previous two injections with BOTOX® with more than 50 Units per eye~* Hypersensitivity to human serum albumin, sucrose, or Botulinum toxin A~* Neuroleptic induced blepharospasm~* Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial~* Treatment with Botulinum toxins for any indication other than BEB within 4 months prior to Baseline and during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- incobotulinumtoxinA (Xeomin) (Type: EXPERIMENTAL): incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All infants who are Appropriate for Gestational Age at Birth and who have a birthweight between 750-1500 grams will be enrolled in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with not more than one drug~* Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Run-in~Exclusion criteria:~* Myocardial infarction, stroke or transient ischemic attack TIA within 6 months prior to informed consent~* Impaired hepatic function~* Renal insufficiency with a creatinine clearance \< 50 mL/min~* Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP-1) analogues, insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors or anti-obesity drugs 3 months prior to informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
- Linagliptin (Type: EXPERIMENTAL): Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
- Sitagliptin (Type: ACTIVE_COMPARATOR): Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. provision of written, informed consent~2. HIV-infected adults at least 18 years of age~3. receiving stable ART including TDF and a r/PI for the previous 6 months~4. no prior PI genotypic resistance or known replication of HIV in patients receiving a PI~5. plasma HIV RNA \< 50 copies/ml for at least the previous 3 months~6. spine or neck of femur t-score ≤ -1.0 (i.e. WHO-defined osteopenia) measured by dual energy x-ray absorptiometry (DEXA)~   Exclusion Criteria:~7. participation in any other clinical trial (unless approved by the study PI)~8. use of TDF for previously active chronic hepatitis B infection~9. receiving or requiring therapy for low BMD (including prior fragility fracture)~10. using oral corticosteroids or inhaled fluticasone~11. virological failure on, or intolerance to, RAL~12. contra-indication to RAL therapy (see appendix 2)~13. breast-feeding~14. pregnancy~15. secondary, endocrinological cause of low BMD:25-hydroxy vitamin D deficiency, hypogonadism: a)symptomatic b)asymptomatic defined by total testosterone \> 25% below lower limit of reference range and/or luteinizing hormone \> 2 x upper limit of normal (ULN),untreated hypothyroidism or hyperparathyroidism according to local reference ranges

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned diagnostic coronary or peripheral artery angiography~* T2DM~* CKD stages 2 and 3, eGFR 30 to 89ml/min per 1.73m2~* Statin naive, or not on statin treatment for at least 14 days~* Withdrawal metformin or aminophylline for 48h before angiography~* Total iodixanol volume~Exclusion Criteria:~* Hypersensitivity to iodine-containing compounds and statins~* Type 1 diabetes mellitus~* Ketoacidosis~* Lactic acidosis~* CKD stages 1,4 or 5 (eGFR≥90ml/min per 1.73m2 or eGFR\<30ml/min per 1.73m2)~* STEMI~* NYHA class IV or hemodynamic instability~* Administration of any iodinated CM within 14 days before randomization~* LDL-C\<1.82mmol/L（70mg/dL）~* Hepatic dysfunction (ALT 3 times greater than upper normal limit)~* Thyreoid insufficiency~* renal artery Stenosis(unilateral \>70％ or bilateral stenosis\>50％)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): perioperative rosuvastatin administration for at least 5 dosages
- control (Type: PLACEBO_COMPARATOR): blank control of perioperative statin administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Online Peer Networked Collaborative Learning for Managing Depressive Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has elevated depressive symptoms~* Has a telephone, e-mail account, computer, and broadband access to the Internet.~* Has basic internet skills and is able to access the internet independently~* Is able to speak and read English.~* Is at least 65 years of age.~* Is able to give informed consent.~Exclusion Criteria:~* Has hearing or voice impairment that would prevent participation in psychotherapy~* Has visual impairment that would prevent completion of assessment materials.~* Is diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance abuse, or other diagnosis for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous.~* Is currently receiving individual psychotherapy or planning to receive psychotherapy during the 8-week treatment phase of the study~* Is planning to be out of town or unavailable for an extended period of time during the study without access to the Internet~* Exhibits severe suicidality, including ideation, plan, and intent.~* Has initiated treatment with an antidepressant in past 14 days. Once patients have been on a stable dose for 14 days and do not have an appointment with a physician or psychiatrist to change this dose, the patient will be eligible based on this criterion.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individual Internet Intervention (III) (Type: EXPERIMENTAL): Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.~(iCBT for late life depression without social network included.)
- Internet Intervention+Peer Supp.(II+PS) (Type: EXPERIMENTAL): Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.~(iCBT for late life depression with social network included.)
- Waitlist Control (WLC) (Type: NO_INTERVENTION): Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing informed consent~* Body mass index (BMI) 18.5-40.0 kg/m\^2 (both inclusive)~* Only for subjects with hepatic impairment (mild, moderate and severe): A diagnosis of cirrhosis due to parenchymal liver disease, classified as Child-Pugh grade A,B or C as assessed by investigator and which is confirmed and documented by medical history, physical examination and at least one of the following: hepatic ultrasound,computerised axial tomography (CT) scan, magnetic resonance imaging (MRI), and/or liver biopsy~* Only for subjects with normal hepatic function: Subjects who are judged to be in good general health based on physical examination, medical history, ECG, vital signs, and the results of biochemistry, coagulation, haematology tests and urinalysis performed during the screening visit, as judged by the investigator~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential not using an adequate contraceptive method throughout the trial including the follow-up period (adequate contraceptive measures as required by local regulation or practice)~* Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg). If white-coat hypertension is suspected at the screening visit a repeated measurement at the screening visit is allowed~* Mental inability, unwillingness or language barrier precluding adequate understanding of or compliance with trial procedures~* Donation of any blood or plasma in the past month or in excess of 400 mL within the 3 months preceding screening, or surgery or trauma with more than 400 mL blood loss within the 3 months preceding screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal hepatic function (Type: EXPERIMENTAL): None
- Mild hepatic impairment (Type: EXPERIMENTAL): None
- Moderate hepatic impairment (Type: EXPERIMENTAL): None
- Severe hepatic impairment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete